Table 1.
Summary of BVA, gain, final VA and mean number of injections in the overall population and subgroups for anti-VEGF and DEX-implant observational studies (BVA: baseline visual acuity, IVI: intravitreal injection.
| Anti-VEGF | DEX-implant | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of eyes | BVA (letters) | Mean gain (letters) | Final VA (letters) | Mean follow-up (months) | Mean IVI | Number of eyes | BVA (letters) | Mean gain (letters) | Max VA (letters) | Mean follow-up (months) | Mean IVI | |
| Overall population | 6842 | 57.3 | +4.7 | 62 | 15.6 | 5.8 | 1703 | 51.5 | +9.6 | 61.2 | 10.3 | 1.6 |
| BVA | ||||||||||||
| ≤ 50 letters | 449 | 42.4 | +4.3 | 46.7 | 13 | 3 | 363 | 39.4 | +10.5 | 49.9 | 9 | 1.2 |
| 50-60 letters | 4773 | 55.7 | +5.8 | 61.7 | 16.3 | 5.8 | 1218 | 54.1 | +9.3 | 63.7 | 11.6 | 1.75 |
| ≥ 60 letters | 1620 | 65.3 | +3.1 | 68.3 | 13.5 | 6.5 | 122 | 68.4 | +8.8 | 76.5 | 9 | 1.8 |
| Initial Status | ||||||||||||
| Naive patients | 781 | 56 | +5 | 61 | 12.3 | 5.2 | 176 | 57.9 | + 12 | 69.9 | 10.8 | 1.9 |
| Non-naïve patients | 413 | 56.9 | + 4.8 | 61.8 | 12.1 | 6.2 | 801 | 48.7 | +8.6 | 57.3 | 9.2 | 1.4 |